![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, November 1, 2022 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical firm pioneering allosteric modulation-based drug discovery and growth (the Company), introduced right now that it has issued 32,636,476 new registered shares at a nominal worth of CHF 0.01 every to Addex Pharma SA, its 100% wholly-owned subsidiary. The new shares, issued from the Company’s approved capital, are listed on the SIX Swiss Exchange. The transaction has been executed to present the Group with further future financing flexibility. The complete variety of issued shares elevated to 97,909,428 at a nominal worth of CHF 0.01 every, while the excellent shares stay unchanged.
Swiss Takeover Board Decision
Upon completion of the above-described capital improve, Addex Pharma SA exceeded the supply threshold of 33 1/3% of the voting rights of the Company. Within this context, the Company has to publish the choice of the Swiss Takeover Board (the TOB) of August 18, 2022:
“The Takeover Board decides:
- Addex Pharma SA is granted an exemption pursuant to Art. 136 para. 1 lit. c of the Financial Market Infrastructure Act (FMIA) from the obligation to make an offer pursuant to Art. 135 FMIA in respect of all listed shares of Addex Therapeutics Ltd in connection with the transaction described in this decision. This exemption from the obligation to make an offer is granted under the condition that (i) Addex Pharma SA reduces its shareholding in Addex Therapeutics Ltd to or below the threshold of 33 1/3% of the share capital in terms of voting rights by March 31, 2023 and that (ii) Addex Pharma SA does not exercise significant influence on the fate of Addex Therapeutics Ltd during the period in which it exceeds the threshold;
- Addex Pharma is required to notify the Swiss Takeover Board within five trading days if it exceeds or falls below the threshold of 33.3% of the share capital and voting rights in Addex Therapeutics Ltd.
- Addex Therapeutics Ltd is required to publish the provisions of the present decision as well as the reference to the right of objection of qualified shareholders pursuant to Art. 6 and 7 TOO.
- This decision will be published on the website of the Swiss Takeover Board following the publication by Addex Therapeutics Ltd in accordance with clause 3 above.
- The fees payable by Addex Pharma SA amount to CHF 20,000.”
The Company’s Board of Directors has determined not to publish a separate report inside the that means of Article 61 para. 3 lit. a of the Takeover Ordinance.
Shareholders of the Company who’ve been holding not less than 3% of the voting rights of the Company, whether or not exercisable or not (a “qualified participation”), because the date of publication of the choice, might file an objection towards the choice of the TOB. The objection should be filed with the TOB (Stockerstrasse 54, 8002 Zurich; fax: +41 44 283 17 40) inside 5 (5) buying and selling days from the date of publication of the choice. The first buying and selling day after the publication of the choice on the TOB’s web site would be the first day of the submitting interval. The objection should comprise a movement, abstract causes and proof of the certified participation as from the date of the publication of the choice.
Verfügung der Übernahmekommission / Décision de la fee des OPA
| (Anm.: da Addex Therapeutics Ltd keine Unternehmensnachrichten auf Deutsch veröffentlicht, wird die gesetzlich vorgeschriebene Deutschübersetzung hier wiedergegeben.)
Nach Vollzug der oben beschriebenen Kapitalerhöhung hat Addex Pharma SA die Angebotsschwelle von 33 1/3% der Stimmrechte der Gesellschaft überschritten. In diesem Zusammenhang hat die Gesellschaft die Verfügung der Übernahmekommission (die UEK) vom 18. August 2022 zu veröffentlichen:
“Die Übernahmekommission verfügt:
Der Verwaltungsrat von Addex Therapeutics Ltd hat entschieden, keine Stellungnahme gemäss Art. 61 Abs. 3 lit. a UEV zu veröffentlichen.
Aktionäre der Gesellschaft, die seit dem Datum der Publikation der Verfügung über 3% der Stimmrechte von Addex Therapeutics Ltd, ob ausübbar oder nicht (eine “qualifizierte Beteiligung”), halten können gegen die Verfügung der UEK Einsprache erheben. Die Einsprache ist innerhalb von fünf (5) Börsentagen nach der Veröffentlichung der Verfügung bei der UEK (Stockerstrasse 54, 8002 Zürich; Fax: +41 44 283 17 40) zu erheben. Der erste Börsentag nach der Publikation der Verfügung auf der Website der UEK ist der erste Tag der Einreichefrist. Die Einsprache muss einen Antrag und eine summarische Begründung sowie den Nachweis der qualifizierten Beteiligung ab dem Datum der Veröffentlichung der Verfügung enthalten.
|
(Remarque: Dans la mesure où Addex Therapeutics Ltd ne publie pas ses communications d’entreprise en français, la traduction française requise par la loi est reproduite ici.)
A l’issue de l’augmentation de capital décrite ci-dessus, Addex Pharma SA a dépassé le seuil d’offre de 33 1/3% des droits de vote d’Addex Therapeutics Ltd. Dans ce contexte, Addex Therapeutics Ltd doit publier la décision de la Commission des OPA (la COPA) du 18 août 2022 :
“La Commission des OPA décide
Le Conseil d’administration d’Addex Therapeutics Ltd a décidé de ne pas publier de prise de place conformément à l’artwork. 61 al. 3 let. a OOPA.
Les actionnaires de la société qui détiennent plus de 3% des droits de vote d’Addex Therapeutics Ltd, exerçables ou non (une “participation qualifiée”), depuis la date de publication de la décision peuvent former opposition contre la décision de la COPA. L’opposition doit être déposée auprès de la COPA (Stockerstrasse 54, 8002 Zurich ; fax : +41 44 283 17 40) dans les cinq (5) jours de bourse suivant la publication de la décision. Le premier jour de bourse suivant la publication de la décision sur le web site web de la COPA est le premier jour du délai de dépôt. L’opposition doit contenir une requête et une motivation sommaire ainsi que la preuve de la participation qualifiée dès la date de la publication de la décision. |
About Addex Therapeutics:
Addex Therapeutics is a clinical-stage pharmaceutical firm targeted on the event and commercialization of an rising class of novel orally obtainable, small molecule medication often called allosteric modulators for neurological issues. Allosteric modulators supply a number of potential benefits over typical, non-allosteric molecules and will supply an improved therapeutic method to typical “orthosteric” small molecule or organic medication. Addex’s allosteric modulator drug discovery platform targets receptors and different proteins which can be acknowledged as important for therapeutic intervention. Addex’s lead drug candidate, ADX71149 (mGlu2 optimistic allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of idea medical trial for the therapy of epilepsy. Addex’s second medical program, dipraglurant (mGlu5 unfavourable allosteric modulator or NAM), is beneath analysis for future growth in a spread of indications. Indivior PLC has licensed Addex’s GABAB PAM program for the event of drug candidates, with a deal with substance use dysfunction. Addex can also be advancing a broad preclinical pipeline, which incorporates growth of a spread of GABAB PAMs for CMT1A, persistent cough and a number of other varieties of ache, mGlu7 NAM for stress associated issues, mGlu2 NAM for delicate neurocognitive issues and despair, M4 PAM for schizophrenia and different types of psychosis, in addition to mGlu4 PAM and mGlu3 PAM. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and commerce beneath the ticker image “ADXN” on every trade.
Contact:
Addex Forward Looking Statements:
This press launch incorporates forward-looking statements inside the that means of the Private Securities Litigation Reform Act of 1995, as amended, together with the flexibility to uncover molecules as a part of the Indivior collaboration, the progress of medical trials and preclinical research, together with the timing of information read-outs from the ADX71149 epilepsy examine, and our meant strategic course. The phrases “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and related expressions are meant to establish forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. Any forward-looking statements on this press launch, comparable to receipt of ongoing analysis funds and timing of the collaboration conclusion, are based mostly on administration’s present expectations and beliefs and are topic to various dangers, uncertainties and vital components which will trigger precise occasions or outcomes to differ materially from these expressed or implied by any forward-looking statements contained on this press launch, together with, with out limitation, uncertainties associated to market situations. These and different dangers and uncertainties are described in larger element within the part entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F for the 12 months ended December 31, 2021, as filed with the SEC on March 10, 2022, the prospectus complement and accompanying prospectus and different filings that Addex Therapeutics might make with the SEC sooner or later. Any forward-looking statements contained on this press launch characterize Addex Therapeutics’ views solely as of the date hereof and shouldn’t be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to replace any forward-looking statements.
